Insider Selling: Outset Medical, Inc. (NASDAQ:OM) CEO Sells $13,192.83 in Stock

Outset Medical, Inc. (NASDAQ:OM) CEO Leslie Trigg sold 10,227 shares of Outset Medical stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $1.29, for a total value of $13,192.83. Following the sale, the chief executive officer now owns 894,624 shares in the company, valued at $1,154,064.96. This trade represents a 1.13 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Leslie Trigg also recently made the following trade(s):

• On Friday, November 15th, Leslie Trigg sold 5,645 shares of Outset Medical stock. The stock was sold at an average price of $0.80, for a total value of $4,516.00.

Outset Medical Stock Down 10.9 %

OM opened at $0.98 on Friday. Outset Medical, Inc. has a 52 week low of $0.44 and a 52 week high of $5.27. The business has a 50 day moving average price of $1.00 and a two-hundred day moving average price of $1.50. The company has a quick ratio of 5.04, a current ratio of 6.49 and a debt-to-equity ratio of 4.12. The company has a market cap of $51.49 million, a PE ratio of -0.36 and a beta of 2.05.

Institutional Investors Weigh In On Outset Medical

Several large investors have recently modified their holdings of the stock. Vanguard Personalized Indexing Management LLC purchased a new stake in Outset Medical in the 2nd quarter valued at approximately $49,000. Ground Swell Capital LLC acquired a new stake in shares of Outset Medical in the 2nd quarter valued at approximately $49,000. National Bank of Canada FI boosted its stake in shares of Outset Medical by 79.2% in the third quarter. National Bank of Canada FI now owns 52,407 shares of the company’s stock valued at $35,000 after buying an additional 23,164 shares in the last quarter. Huntington National Bank grew its holdings in Outset Medical by 46.2% during the third quarter. Huntington National Bank now owns 63,306 shares of the company’s stock worth $43,000 after acquiring an additional 20,000 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in Outset Medical in the second quarter worth $259,000.

Analysts Set New Price Targets

Separately, Royal Bank of Canada restated a “sector perform” rating and set a $3.00 target price on shares of Outset Medical in a research report on Tuesday.

About Outset Medical

Outset Medical, Inc, a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company offers Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables.